Dosage guide

Hexarelin Dosage

GH secretagogue / GHRP (synthetic hexapeptide)

Hexarelin has no approved label, so every figure here traces back to published human pharmacology studies rather than a prescribing guideline. Those studies gave it intravenously at about 1 to 2 mcg/kg and subcutaneously at similar mcg/kg doses, which works out to roughly 100 mcg for many adults.[1][2][3]

Reviewed for accuracy · Last reviewed July 8, 2026

Dosing

Doses below describe what human studies used, not a recommendation. Hexarelin is investigational and has no approved dose:

Setting studiedDose used
GH-release studies (IV)~1 – 2 mcg/kg
Dose-response (IV)up to ~1 mcg/kg
Subcutaneous route~1.5 – 3 mcg/kg
Rough per-dose figurecommonly around 100 mcg
Figures traced to published human pharmacology studies, not a prescribing guideline. Effect can attenuate with continued use.

A dose-response study found a half-maximal GH response near 0.48 mcg/kg IV, with the curve plateauing at higher doses. Treat these numbers as a description of what was studied, not a recommendation.

A documented caveat for GHRPs is that the GH-releasing effect partially desensitizes with continued use, more so with continuous than intermittent dosing. Reviews note this attenuation without endorsing any specific cycling schedule.

FAQ

What hexarelin doses were used in studies?Human studies used roughly 1 to 2 mcg/kg intravenously (about 100 mcg for many adults) and similar mcg/kg doses subcutaneously. There is no approved dose because hexarelin is investigational.
Why might the effect weaken over time?Reviews of GHRPs report partial desensitization of the GH response with continued use, greater during continuous than intermittent administration.

References

  1. Growth Hormone-Releasing Activity of Hexarelin, a New Synthetic Hexapeptide, After Intravenous, Subcutaneous, Intranasal, and Oral Administration in ManJournal of Clinical Endocrinology & Metabolism · 1994 · PMID 8126144 · DOI 10.1210/jcem.78.3.8126144
  2. Hexarelin-Induced Growth Hormone, Cortisol, and Prolactin Release: A Dose-Response StudyJournal of Clinical Endocrinology & Metabolism · 1996 · PMID 8954038 · DOI 10.1210/jcem.81.12.8954038
  3. Growth Hormone-Releasing PeptidesEuropean Journal of Endocrinology · 1997 · DOI 10.1530/eje.0.1360445
Tracking a research protocol? PepHub can log your doses and timing.Coming soon

This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.